A recent study has demonstrated a significant decrease in cases of human papilloma virus infection in England since the introduction of a bivalent vaccine in 2008.
Browsing: Clinical > Vaccines
Through a process of elimination, researchers have identified membrane surface proteins on T. pallaidum, which can be targeted by immune antibodies.
At ASM Microbe GeoVax have spoken on the development of single-dose vaccines for emerging diseases using their MVA ‘Plug and Play’ platform technology.
In our latest interview we ask Seth Berkley, who has been CEO of Gavi since 2011, about new vaccines, the importance of collaboration and the challenges facing access to vaccinations.
In this interview Sally, a Senior Research Fellow at Imperial College London’s Faculty of Medicine (London, UK), speaks about her work on issues relating to the vaccination and screening of migrants, in addition to discussing some of the wider issues facing migrant’s access to healthcare in Europe.
Rabies elimination is achievable and cost-effective, but decades of research have failed to translate into multi-national efforts in the worst-affected areas. So why is the ancient rabies virus still terrorizing the lives of so many people across the globe?
Research presented at ECCMID suggests unvaccinated teenagers and adults were at highest risk of developing measles, whilst the biggest threat of mortality was to those under the age of two.
A novel initiative is working to ensure that approximately 1 billion individuals are vaccinated against yellow fever across 27 African countries by 2026.
Take a look at how advancements in genetic engineering has led to advances in vaccine manufacturing, with a divergence from live cell cultures to recombinant production in host cells.